drugset
drugset / Trial / NCT00146159

Study Evaluating Mitoxantrone in Multiple Sclerosis

NCT00146159 ↗

Phase 3 Terminated 336 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients.

Timeline

Start
2005-03
Primary completion
2007-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 5 mg/m2 —
Subject Mitoxantrone Small molecule 9 mg/m2 —
Subject Mitoxantrone Small molecule 12 mg/m2 —

Indications

secondary progressive multiple sclerosis